VIDEO: New CAR T-cell product may reduce side effects in ALL
Click Here to Manage Email Alerts
In this video, Douglas Tremblay, MD, discusses the results of a study into CD19-targeted chimeric antigen receptor T-cell therapy in acute lymphocytic leukemia presented at ESMO Congress 2024.
Tremblay, an assistant professor of medicine at the Icahn School of Medicine at Mount Sinai, highlighted the study, which tested a new CAR T-cell product that was aimed to reduce the risk for immune effector cell-associated neurotoxicity syndrome (ICANS) and cytokine release syndrome.
“I think this is kind of an interesting way, instead of normally waiting for ICANS or CRS to develop and then giving an IL6 antibody-blocking agent, to incorporate IL6 silencing into the actual CAR construct to be able to prevent these complications from happening,” Tremblay said.
Collapse
Click Here to Manage Email Alerts